LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.40M
Average 0.23M
Returns on capital
LB Pharmaceuticals Inc Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-8.4%
avg 31.6%
ROIC
-9.9%
avg -75.0%
ROA
-8.1%
avg -69.2%
Analysis
ROA is currently the strongest return metric at -8.1% versus its period average of -69.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Heather D. Turner | Chief Executive Officer & Director | USD 1.02M | 53 | — | — |
Soffer | Chief Operating & Business Officer | USD 644.8K | 49 | — | — |
Anna Eramo | Advisor | USD 616.93K | 51 | — | — |
Susan G. Kozauer | Chief Medical Officer | USD 616.93K | 54 | — | — |
Christopher Zergebel | Senior Vice President of Clinical Operations | — | — | — | — |
Joseph Miller | Chief Financial Officer | — | 52 | — | — |
Lindsay Beaupre | Senior VP of People & Culture | — | — | — | — |
Minako Pazdera | General Counsel | — | — | — | — |
James Rawls | Senior Vice President of Regulatory Affairs | — | — | — | — |
Richard Silva | Senior Vice President of Technical Operations | — | 58 | — | — |
Ellen Rose | Senior Vice President of Corporate Affairs | — | — | — | — |
Kaya Pai Panandiker | Chief Commercial Officer | — | 49 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$28.62
Sells
0
$0.00
Net Transaction Value
+$28.62
Net buying
Most Active
Deep Track Biotechnology Master Fund, Ltd.
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 30, 26Jul 30, 2026 | Deep Track Biotechnology Master Fund, Ltd. Direct | Buy | $28.6$28.62 |
Summary
Insiders reported 1 buys worth $28.62 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $28.62. Deep Track Biotechnology Master Fund, Ltd. was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does LB Pharmaceuticals Inc Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about LBRX's management, answered from reported figures.
Who manages LBRX?
LB Pharmaceuticals Inc Common Stock (LBRX) lists 12 active executives. The top listed executive is Anna Eramo, Advisor.
Are LBRX insiders buying or selling?
Recent insider activity shows net buying of $14.89M.
Continue the stock analysis
Jump to another research area for this company.